新東方(09901.HK)終止認購東方甄選(01797.HK)股份 承諾聯交所場內增持
新東方-S(09901.HK)公布,終止據特別授權認購東方甄選(01797.HK)股份,主要基於商業考量後之結果,包括東方甄選股份的近期股價。原訂於2月7日召開的股東特別大會經已取消。
新東方與東方甄選行政總裁俞敏洪仍對東方甄選前景及業務潛力具有信心,並各自承諾以市價在聯交所購買合共價值7億元的東方甄選股份,其中,新東方承諾購買總值6.6億元股份。購股行動將自即日起六至十二個月期間逐步進行。
東方甄選原計劃向新東方配售5,135.23萬股新股,每股作價31.75元,集資淨額16.28億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.